Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04080206 · ClinicalTrials.gov registry record · Phase 2
A Safety Study of 188-0551 Spray Versus Reference Listed Drug (RLD) in Adult Subjects With Plaque Psoriasis
A Phase 2 study, sponsored by Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT04080206 is a Phase 2 study that has completed, run by Therapeutics. The registered enrollment target is 55 participants.
The verdict
NCT04080206, a Phase 2 study, has completed, sponsored by Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
Adrenal suppression effects of corticosteroids are among the most important safety concerns for this group of products. This study is to determine and compare the adrenal suppression potential and the pharmacokinetic (PK) properties of 188-0551 Spray versus an FDA-approved drug (also known as a "Reference Listed Drug" \[RLD\]) under maximal use conditions when applied twice daily (approximately every 12 hours) in adult subjects with stable, moderate to severe, plaque psoriasis.
Interventions
- DRUG 188-0551 Spray
- DRUG RLD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2020-04-07 |
| Est. Completion | 2021-01-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04080206
The ClinicalTrials.gov registry entry for NCT04080206 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Therapeutics, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 188-0551 Spray is the first listed.
NCT04080206 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04080206 about?
NCT04080206 is a clinical study titled "A Safety Study of 188-0551 Spray Versus Reference Listed Drug (RLD) in Adult Subjects With Plaque Psoriasis". Adrenal suppression effects of corticosteroids are among the most important safety concerns for this group of products. This study is to determine and compare the adrenal suppression potential and the pharmacokinetic (PK) properties of 188-0551 Spray versus an FDA-approved drug (also known as a "Ref...
What is the current status of trial NCT04080206?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2020-04-07. Estimated completion is 2021-01-20.
What interventions are being tested in trial NCT04080206?
The interventions under investigation include: 188-0551 Spray (DRUG), RLD (DRUG).
Who is sponsoring clinical trial NCT04080206?
This trial is sponsored by Therapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.